SLXN Silexion Therapeutics successfully initiates phase 2/3 clinical trial of sil204 in locally advanced pancreatic cancer at Tel Aviv soura

SLXN Silexion Therapeutics successfully initiates phase 2/3 clinical trial of sil204 in locally advanced pancreatic cancer at Tel Aviv sourasky Medical center Silexion Therapeutics Corp - receives all regulatory approvals for sil204 trial in Israel as of July 29, 2026 - Additional israeli and German sites expected to join sil204 phase 2/3 trial in coming months